To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Inflammatory biomarkers i… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Inflammatory biomarkers in Alzheimer's disease plasma.

Journal article
Authors Angharad R Morgan
Samuel Touchard
Claire Leckey
Caroline O'Hagan
Alejo J Nevado-Holgado
Frederik Barkhof
Lars Bertram
Olivier Blin
Isabelle Bos
Valerija Dobricic
Sebastiaan Engelborghs
Giovanni Frisoni
Lutz Frölich
Silvey Gabel
Peter Johannsen
Petronella Kettunen
Iwona Kłoszewska
Cristina Legido-Quigley
Alberto Lleó
Pablo Martinez-Lage
Patrizia Mecocci
Karen Meersmans
José Luis Molinuevo
Gwendoline Peyratout
Julius Popp
Jill Richardson
Isabel Sala
Philip Scheltens
Johannes Streffer
Hikka Soininen
Mikel Tainta-Cuezva
Charlotte Teunissen
Magda Tsolaki
Rik Vandenberghe
Pieter Jelle Visser
Stephanie Vos
Lars-Olof Wahlund
Anders Wallin
Sarah Westwood
Henrik Zetterberg
Simon Lovestone
B Paul Morgan
Published in Alzheimer's & dementia : the journal of the Alzheimer's Association
Volume 15
Issue 6
Pages 776-787
ISSN 1552-5279
Publication year 2019
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 776-787
Language en
Subject categories Clinical Medicine


Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?